Skip to main content

Main menu

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart
  • Log out

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions

More pressure on pulmonary hypertension

M. Humbert
European Respiratory Review 2009 18: 1-3; DOI: 10.1183/09059180.00011101
M. Humbert
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

The European Respiratory Review is structured around a “theme of the month”. I am delighted to introduce pulmonary hypertension (PH) as the first theme of the new Review.

PH describes a group of devastating diseases, comprising idiopathic and associated/secondary forms, which cause breathlessness, loss of exercise capacity and death due to elevated pulmonary artery pressure and subsequent right heart failure [1]. Pulmonary arterial hypertension (PAH) is defined by an elevation of the mean pulmonary artery pressure above 25 mmHg at rest and/or 30 mmHg during exercise without elevation of the pulmonary capillary wedge pressure (≤15 mmHg) [1]. The underlying pathophysiological mechanism is extensive pulmonary artery remodelling [2]. PH was previously classified into two categories, namely primary or secondary PH, depending on the absence or presence of identifiable causes or risk factors [1]. In the second (1998), third (2003), and fourth (2008) World Symposium on PH, a detailed clinical classification of the disease was agreed upon. The 2003 version is shown in table 1 [1]. The main subcategories share similarities in pathogenetic mechanisms, clinical presentation and therapeutic options, allowing clinicians to conduct trials using homogeneous groups of patients. Similarly, basic science specialists have attempted to describe pathophysiological mechanisms in the same homogeneous groups of patients with PH.

PAH

This includes cases without identifiable cause or risk factors, so-called idiopathic PAH (sporadic appearance) and familial PAH [1]. For these subgroups, mutations in the bone morphogenetic protein (BMP)/transforming growth factor-β superfamily (BMPR2, activin receptor-like kinase-1 and endoglin) are now known to play a crucial role [3]. However, genetic/environmental factors are likely to be the “double hit”, favouring the start of the disease [2]. The other subgroups include a number of conditions or diseases of known causes associated with the appearance of PAH [1]. Among the associated conditions, connective tissue disorders such as systemic sclerosis are major causes of PAH, with >10% of systemic sclerosis patients developing this severe life-threatening complication [4]. All PAH forms have the localisation of remodelling lesions to the small pulmonary muscular arterioles in common [2]. In addition, they may be linked with significant venous or capillary involvement, namely pulmonary veno-occlusive disease and pulmonary capillary haemangiomatosis, conditions characterised by a certain degree of refractoriness to usual PAH therapies [1, 5].

PH WITH LEFT HEART DISEASE

This category consists predominantly of left-sided valvular or myocardial diseases, exerting mechanical strain on the pulmonary vasculature due to congestion [1]. Such conditions passively affect the pulmonary vasculature and are not usually part of the research priorities of the respiratory community. Nevertheless, studies are now focusing on this subgroup of patients who may sometimes develop severe pulmonary vascular disease.

PH ASSOCIATED WITH LUNG DISEASES AND/OR HYPOXIA

Within this category, the predominant cause is inadequate oxygenation of arterial blood as a result of either lung disease, impaired control of breathing or residence at high altitude [1]. Hypoxia-driven molecular mechanisms presumably play an important role in this group, but it remains unclear why some patients develop severe out of proportion PH [6, 7]. In addition, inflammatory mechanisms linked to the lung disease may contribute to the development of the pulmonary vascular disease [8].

PH DUE TO CHRONIC THROMBOTIC AND/OR EMBOLIC DISEASE

This category includes either chronic thromboembolic PH [9] due to proximal organised material in large pulmonary arteries, which can benefit from pulmonary endarterectomy, or more peripheral obstruction similar to those appearing in the small vessels in idiopathic PAH [9]. Abnormalities of coagulation and fibrinolysis control are assumed to represent the decisive trigger events [9].

MISCELLANEOUS

This category involves PH linked with various, mostly inflammatory, disorders. Sarcoidosis and histiocytosis X represent major conditions in this subgroup [1].

Epidemiological data are not available for the entire field of PH. The largest and most recent national registries on PAH have been reported in 2006 in France [10] and 2007 in Scotland (UK) [11]. Prevalence rates for PAH as a whole vary among regions in France, ranging from five cases per million per year to 25 cases per million per year [10]. Data from Scotland indicate a prevalence ranging from 26 to 52 cases per million [11]. In addition, three quarters of the detected cases are in New York Heart Association functional class III or IV when diagnosed, a stage at which survival is limited despite available treatments [10]. Similar results have been reported in the USA by the Chicago group [12]. This information supports the fact that early detection should be promoted in high-risk populations, and that PH should be considered and screened for in patients displaying symptoms, such as unexplained dyspnoea. With a yearly incidence of two per million, PAH fulfils the criteria of a rare disease, with a higher appearance in females compared with males and a mean age at diagnosis of <50 yrs [10, 13]. Sex differences are also true for other categories of the disease, such as connective tissue disease-associated PAH, which is much more frequent in females compared with males [10].

Survival of untreated idiopathic familial PAH is extremely poor, with median survival ranging from 2 to 3 yrs [14]. This is similarly true for many other categories of PH, such as connective tissue disease-associated cases [15]. Over the past few years, various therapeutic strategies have been developed, which include different types of prostanoids, endothelin-receptor antagonists and phosphodiesterase inhibitors [16–19]. These agents were shown to relieve dyspnoea, improve exercise capacity and, not proven for all approaches, survival in these patients [16]. Nevertheless, we are still far from curing PH and further progress in drug development is urgently needed to achieve long-term survival with better quality of life.

PH has a multifactorial pathobiology. Next to vasoconstriction and in situ thrombosis, remodelling of all layers of the pulmonary vessel wall represents the hallmark of this disease, with proliferating resident cell types (endothelial, smooth muscle and adventitial fibroblasts), inflammatory cells and platelets, as well as circulating progenitor cells coming into close interplay [2]. Loss of endothelial function with lack of production of vasodilatory and anti-proliferative agents, such as nitric oxide and prostacyclin and their downstream cyclic nucleotides, was found to be a key event, providing a starting point for therapies based on these agents [2]. In contrast, potent vasoconstrictors, such as the endothelin-1 pathway, are known to be upregulated, again serving as a basis for novel therapeutic approaches [2]. Most importantly, going far beyond their immediate effect on vasomotor control, all these pathways have a major impact on the long-term balance of proliferation and apoptosis of the lung vascular cells, i.e. affect remodelling events [2, 20]. Notably, next to the resident vascular cell types involved in the remodelling, recruitment of circulating progenitor cells and different leukocyte types is controlled by these pathways and by an as yet only partially understood lung vascular chemokine system [8].

In the present issue of the European Respiratory Review, an update by Souza and Jardim [21] will discuss novel information on several forms of pulmonary hypertension. In addition, other chapters will emphasise some important aspects of pulmonary vascular medicine, including pulmonary hypertension complicating hereditary haemorrhagic telangiectasia [22, 23], pulmonary hypertension in high-altitude residents [24], pulmonary hypertension in children [25], chronic thromboembolic pulmonary hypertension [26], and novel therapeutic strategies such as inhaled prostaglandins [27] and soluble guanylate cyclase stimulation, an emerging option in pulmonary hypertension therapy [28].

Statement of interest

None declared.

Provenance

Submitted article, peer reviewed.

View this table:
  • View inline
  • View popup
Table. 1—

Diagnostic classification of pulmonary hypertension

  • Received January 3, 2009.
  • Accepted January 3, 2009.
  • © ERSJ Ltd

References

  1. ↵
    Simonneau G, Galiè N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43: Suppl. 12 5S–12S.
    OpenUrlCrossRefPubMed
  2. ↵
    Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: Suppl. 12 13S–24S.
    OpenUrlCrossRefPubMed
  3. ↵
    Sztrymf B, Coulet F, Girerd B, et al. Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation. Am J Respir Crit Care Med 2008; 177: 1377–1383.
    OpenUrlCrossRefPubMed
  4. ↵
    Hachulla E, Gressin V, Guillevin L, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005; 52: 3792–3800.
    OpenUrlCrossRefPubMed
  5. ↵
    Montani D, Price LC, Dorfmüller P, et al. Pulmonary veno-occlusive disease. Eur Respir J 2009; 33: 189–200.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Chaouat A, Naeije R, Weitzenblum E. Pulmonary hypertension in COPD. Eur Respir J 2008; 32: 1371–1385
  7. ↵
    Sommer N, Dietrich A, Schermuly RT, et al. Regulation of hypoxic pulmonary vasoconstriction: basic mechanisms. Eur Respir J 2008; 32: 1639–1651.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    Dorfmüller P, Balabanian K, Perros F, Humbert M. Inflammation in pulmonary arterial hypertension. Eur Respir J 2003; 22: 358–363.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    Dartevelle P, Fadel E, Mussot S, et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J 2004; 23: 637–648.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173: 1023–1030.
    OpenUrlCrossRefPubMed
  11. ↵
    Peacock A, Murphy NF, McMurray JJV, Caballero L, Stewart S. An epidemiological study of pulmonary arterial hypertension in Scotland. Eur Respir J 2007; 30: 104–109.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Thenappan T, Shah SJ, Rich S. Gomberg-Maitland. A USA-based registry for pulmonary arterial hypertension: 1982–2006. Eur Respir J 2007; 30: 1103–1110.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    Humbert M. The burden of pulmonary hypertension. Eur Respir J 2007; 30: 1–2.
    OpenUrlFREE Full Text
  14. ↵
    D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Ann Int Med 1991; 115: 343–349.
    OpenUrlCrossRefPubMed
  15. ↵
    Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972–2002. Ann Rheum Dis 2007; 66: 940–944.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. New Engl J Med 2004; 351: 1425–1436.
    OpenUrlCrossRefPubMed
  17. Gomberg-Maitland M, Olschewski H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J 2008; 31: 891–901.
    OpenUrlAbstract/FREE Full Text
  18. Dupuis J, Hoeper MM. Endothelin receptor antagonists in pulmonary arterial hypertension. Eur Respir J 2008; 31: 407–415.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    Wilkins MR, Wharton J, Grimminger F, Ghofrani HA. Phosphodiesterase inhibitors for the treatment of pulmonary hypertension. Eur Respir J 2008; 32: 198–209.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    Perros F, Montani D, Dorfmuller P, et al. Platelet derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2008; 178: 81–88.
    OpenUrlCrossRefPubMed
  21. ↵
    Souza R, Jardim C. Trends in pulmonary arterial hypertension. Eur Respir Rev 2009; 18: 7–12
  22. ↵
    Shovlin CL, Gibbs JSR, Jackson JE. Management of pulmonary arteriovenous malformations in pulmonary hypertensive patients: a pressure to embolise? Eur Respir Rev 2009; 18: 4–6
  23. ↵
    Montani D, Price LC, Girerd B, et al. Fatal rupture of pulmonary arteriovenous malformation in hereditary haemorrhagic telangiectasis and severe PAH. Eur Respir Rev 2009; 18: 42–46
  24. ↵
    Xu XQ, Jing ZC. High-altitude pulmonary hypertension. Eur Respir Rev 2009; 18: 13–17
  25. ↵
    Beghetti M. Paediatric pulmonary hypertension: monitoring progress and identifying unmet needs. Eur Respir Rev 2009; 18: 18–23
  26. ↵
    Lang IM. Managing chronic thromboembolic pulmonary hypertension: pharmacological treatment options. Eur Respir Rev 2009; 18: 24–28
  27. ↵
    Olschewski H. Inhaled iloprost for the treatment of pulmonary hypertension. Eur Respir Rev 2009; 18: 29–34
  28. ↵
    Ghofrani HA, Grimminger F. Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy. Eur Respir Rev 2009; 18: 35–41
PreviousNext
Back to top
View this article with LENS
Vol 18 Issue 111 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
More pressure on pulmonary hypertension
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
More pressure on pulmonary hypertension
M. Humbert
European Respiratory Review Mar 2009, 18 (111) 1-3; DOI: 10.1183/09059180.00011101

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
More pressure on pulmonary hypertension
M. Humbert
European Respiratory Review Mar 2009, 18 (111) 1-3; DOI: 10.1183/09059180.00011101
Reddit logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • PAH
    • PH WITH LEFT HEART DISEASE
    • PH ASSOCIATED WITH LUNG DISEASES AND/OR HYPOXIA
    • PH DUE TO CHRONIC THROMBOTIC AND/OR EMBOLIC DISEASE
    • MISCELLANEOUS
    • Statement of interest
    • Provenance
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Clinical and prognostic value of ventilatory efficiency in cardiorespiratory disorders
  • Guidance production before evidence generation for critical issues: COVID-19
  • Modulator treatment for people with cystic fibrosis
Show more Editorial

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERR

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising
  • Sponsorship

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN: 0905-9180
Online ISSN: 1600-0617

Copyright © 2023 by the European Respiratory Society